Susquehanna International Group, LLP Age X Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.33 - $0.74 $189 - $424	573 Added 2.36%	24,849 $9,000
Q3 2023 Nov 14, 2023	SELL	$0.67 - $0.85 $12,969 - $16,454	-19,358 Reduced 44.36%	24,276 $16,000
Q2 2023 Aug 11, 2023	BUY	$0.45 - $0.89 $5,867 - $11,603	13,038 Added 42.61%	43,634 $38,000
Q1 2023 May 16, 2023	SELL	$0.56 - $0.8 $12,199 - $17,428	-21,785 Reduced 41.59%	30,596 $20,000
Q4 2022 Feb 14, 2023	BUY	$0.54 - $0.68 $28,285 - $35,619	52,381 New	52,381 $28,000
Q2 2022 Aug 15, 2022	SELL	$0.57 - $1.0 $8,430 - $14,790	-14,790 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.65 - $1.2 $7,625 - $14,078	-11,732 Reduced 44.23%	14,790 $13,000
Q4 2021 Feb 14, 2022	BUY	$0.53 - $1.09 $14,056 - $28,908	26,522 New	26,522 $29,000
Q4 2019 Feb 14, 2020	SELL	$1.25 - $1.82 $13,257 - $19,302	-10,606 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$1.96 - $3.38 $22,151 - $38,200	-11,302 Reduced 51.59%	10,606 $21,000
Q2 2019 Aug 16, 2019	BUY	$2.58 - $4.92 $4,125 - $7,867	1,599 Added 7.87%	21,908 $80,000
Q2 2019 Aug 14, 2019	BUY	$2.58 - $4.92 $52,397 - $99,920	20,309 New	20,309 $75,000

Ticker AGE
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,945,100
Description
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-rel...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.